Treatment Efficacy Rankings is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.
Rankings of treatments by clinical efficacy, disease modification evidence, safety profile, and clinical utility across neurodegenerative diseases.
| Rank |
Treatment |
Efficacy |
Evidence Level |
| 1 |
Lecanemab |
-27% clinical decline |
Phase 3, FDA approved |
| 2 |
Donanemab |
-35% clinical decline |
Phase 3, FDA approved |
| 3 |
Aducanumab |
Variable |
Phase 3, FDA approved |
| 4 |
Atabecestat |
Failed |
Phase 2/3 |
¶ Disease-Modifying Candidates
| Rank |
Treatment |
Survival Benefit |
Function |
| 1 |
Tofersen |
+6 mo (SOD1) |
+3 points ALSFRS-R |
| 2 |
Riluzole |
+2-3 months |
Minimal |
| 3 |
Edaravone |
None |
Slower decline |
| 4 |
Relyvrio |
+6 months |
+2 points |
PSP is a 4R-tauopathy with no FDA-approved disease-modifying therapies. Treatment focuses on symptomatic management, neuroprotection, and rehabilitation. See the PSP Treatment page for detailed protocols and the CBS/PSP Treatment Rankings for evidence-scored interventions.
| Rank |
Treatment |
Score |
Evidence |
Notes |
| 1 |
Structured exercise (aerobic + resistance + balance) |
68 |
High |
Most effective intervention; improves mobility and reduces falls[8][9] |
| 2 |
Mediterranean/MIND diet |
64 |
High |
Anti-inflammatory, neuroprotective[^10] |
| 3 |
Multidisciplinary rehabilitation (PT/OT/SLP) |
61 |
High |
Essential for maintaining function[^11] |
| 4 |
Rasagiline (MAO-B inhibitor) |
58 |
Moderate |
May provide modest symptomatic benefit[^12] |
| 5 |
Rapamycin (mTOR inhibition) |
57 |
Preclinical |
Autophagy induction; human trials ongoing[^13] |
| 6 |
TUDCA/UDCA (bile acid therapy) |
56 |
Moderate |
Neuroprotective; Phase 2 trials[^14] |
| 7 |
Vitamin D supplementation |
55 |
Moderate |
Safety profile; many patients deficient[^15] |
| 8 |
Spermidine (autophagy induction) |
55 |
Preclinical |
Promising mechanism[^16] |
| 9 |
Photobiomodulation (PBM) |
55 |
Emerging |
Non-invasive neurostimulation[^17] |
| 10 |
Cognitive reserve/mental engagement |
51 |
Moderate |
May slow progression[^18] |
| Rank |
Treatment |
Score |
Evidence |
| 11 |
Resveratrol/SIRT1 activation |
51 |
Preclinical |
| 12 |
Creatine supplementation |
50 |
Moderate |
| 13 |
Methylene Blue/LMTX |
50 |
Phase 3 |
| 14 |
Coenzyme Q10 |
48 |
Moderate |
| 15 |
Ambroxol (GCase chaperone) |
48 |
Preclinical |
| 16 |
Omega-3 fatty acids (DHA/EPA) |
48 |
Moderate |
| 17 |
Sleep optimization/apnea treatment |
47 |
Moderate |
| 18 |
NACET |
46 |
Preclinical |
| 19 |
Sulforaphane/Nrf2 activation |
44 |
Preclinical |
| 20 |
Deferiprone (iron chelation) |
42 |
Phase 2 |
| Symptom |
First-Line |
Evidence |
| Motor/Bradykinesia |
Levodopa (trial) |
Limited response (~20-30%) |
| Falls/Postural instability |
Physical therapy |
Strong |
| Neck dystonia (retrocollis) |
Botulinum toxin |
Moderate |
| Depression |
SSRIs |
Moderate |
| Apathy |
Methylphenidate |
Moderate |
| Pseudobulbar affect |
Dextromethorphan/quinidine |
FDA-approved |
- Tideglusib (GSK-3β inhibitor): Phase 2 completed[^39]
- Rapamycin: mTOR inhibition for autophagy
- ApoE-targeted therapies: Genetic subset considerations
CBS presents unique challenges due to heterogeneous pathology. Like PSP, no disease-modifying therapies exist. Treatment is symptomatic and rehabilitative. See the CBS Treatment page for detailed protocols.
| Rank |
Treatment |
Score |
Evidence |
Notes |
| 1 |
Structured exercise (aerobic + resistance + balance) |
68 |
High |
Foundation of treatment[8][9] |
| 2 |
Mediterranean/MIND diet |
64 |
High |
Anti-inflammatory[^10] |
| 3 |
Multidisciplinary rehabilitation (PT/OT/SLP) |
61 |
High |
Critical for function[^11] |
| 4 |
Rasagiline (MAO-B inhibitor) |
58 |
Moderate |
May help[^12] |
| 5 |
Rapamycin (mTOR inhibition) |
57 |
Preclinical |
Autophagy[^13] |
| 6 |
TUDCA/UDCA (bile acid therapy) |
56 |
Moderate |
Neuroprotective[^14] |
| 7 |
Vitamin D supplementation |
55 |
Moderate |
Generally safe[^15] |
| 8 |
Spermidine (autophagy induction) |
55 |
Preclinical |
Promising[^16] |
| 9 |
Photobiomodulation (PBM) |
55 |
Emerging |
Non-invasive[^17] |
| 10 |
Cognitive reserve/mental engagement |
51 |
Moderate |
May help[^18] |
| Symptom |
First-Line |
Evidence |
| Motor symptoms |
Levodopa trial |
Poor response (~10-20%) |
| Dystonia |
Botulinum toxin |
Effective |
| Myoclonus |
Levetiracetam, clonazepam |
Moderate |
| Cognitive impairment |
Donepezil, rivastigmine |
Modest |
| Apathy |
Methylphenidate |
Moderate |
| Depression/Anxiety |
SSRIs |
Standard |
- Tau immunotherapies: Gantenerumab, semorinemab (failed in CBS)
- Tideglusib: GSK-3β inhibitor (Phase 2)[^39]
- Lithium: Low-dose (Phase 2)[^30]
- ADAS-Cog: Alzheimer's cognition (0-70)
- MDS-UPDRS: Parkinson's motor (0-132)
- ALSFRS-R: ALS function (0-48)
- UHDRS: Huntington's (0-400)
- Amyloid PET SUVr reduction
- CSF p-tau/t-tau ratio
- Volumetric MRI loss rate
- Memantine — Minimal side effects
- Donepezil — Generally well-tolerated
- Rasagiline — Once-daily
- ARIA (brain edema/hemorrhage): Aducanumab, Lecanemab, Donanemab
- Liver toxicity: Many Phase 1 compounds
- Cardiac: Some dopamine agonists
| Treatment |
Efficacy |
Evidence Level |
FDA Approved |
| Donepezil |
Moderate |
High (RCTs) |
Yes |
| Rivastigmine |
Moderate |
High |
Yes |
| Memantine |
Modest |
Moderate |
Yes |
| Aducanumab |
Variable |
Moderate |
Yes |
| Treatment |
Efficacy |
Onset |
Duration |
| Carbidopa/levodopa |
High |
Fast |
Years |
| Dopamine agonists |
Moderate |
Moderate |
Years |
| MAO-B inhibitors |
Modest |
Moderate |
Years |
| Deep brain stimulation |
High |
Fast |
Years |
- Amyloid removal: Lecanemab > Aducanumab > Donanemab
- Tau targeting: Semorinemab (mixed results), tilavonemab (failed)
- Alpha-synuclein: Cinamerisen (ongoing trials)
- Neuroinflammation: TREM2 agonists (early stage)
- Advanced (Phase 3+): Lecanemab, Donanemab, Inosine
- Mid-stage (Phase 2): TREM2 agonists, gene therapies
- Early (Phase 1): Novel small molecules, cell therapies
This page is auto-maintained. Last updated: 2026-03-15
¶ Coverage Gaps and Needs Work
This section identifies missing or underdeveloped treatment pages that need coverage.
The following treatments have no dedicated pages but are important for neurodegenerative disease management:
| Priority |
Disease |
Treatment |
Status |
Notes |
| High |
Parkinson's |
Carbidopa |
Missing |
Levodopa companion drug, essential |
| High |
Parkinson's |
Opicapone |
Missing |
COMT inhibitor, once-daily |
| High |
Parkinson's |
Inosine |
Missing |
Phase 3, urate elevation for neuroprotection |
| High |
Parkinson's |
GM1 Ganglioside |
Missing |
Phase 2/3, neuroprotection |
| High |
FTD |
Frontotemporal Dementia Treatments |
Missing |
No approved DMTs, symptomatic care needed |
| High |
CBS |
Corticobasal Syndrome Treatments |
Missing |
Rare tauopathy, no approved treatments |
| High |
PSP |
Progressive Supranuclear Palsy Treatments |
Missing |
Tauopathy, no approved DMTs |
Some treatment pages exist but need expansion:
| Treatment |
Current Words |
Priority |
Gap |
| Ropinirole |
6289 |
Medium |
Missing recent trials |
| Rotigotine |
6620 |
Medium |
Missing patch delivery details |
| Entacapone |
6231 |
Low |
Needs COMT mechanism details |
Based on this analysis, the following tasks should be created:
- Create Carbidopa treatment page — Levodopa companion drug, essential for PD treatment
- Create Opicapone treatment page — Third-generation COMT inhibitor
- Create Inosine treatment page — Phase 3 disease-modifying candidate for PD
- Create FTD/CBS/PSP treatment overview pages — These tauopathies lack treatment coverage